RxDoctor Payments Data

Bethany Cahill

Family · Norfolk, VANPI 1548894165

Payments from drug & device makers

$3,331in general payments, 2019–2025

Across 155 payments — averaging $21.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$641
  • AstraZeneca$282
  • Lilly USA, LLC$235
  • Pfizer$198
  • Novartis$194
  • Amgen$193
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$3,331100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,331 in reported general payments places this provider in the 90th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$37,362
Medicare patients
84
Services billed
409

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol107$106,330
TrulicityDulaglutide67$80,541
OzempicSemaglutide61$75,391
EliquisApixaban66$69,864
JardianceEmpagliflozin32$28,392
JanuviaSitagliptin Phosphate23$27,765
XareltoRivaroxaban12$20,129
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$16,112
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog20$11,330
Albuterol Sulfate HfaAlbuterol Sulfate172$4,232
Atorvastatin Calcium365$3,356
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$2,736
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate20$2,676
Duloxetine Hcl91$2,641
Amlodipine Besylate360$2,050

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$282$106,330107 claims
Lilly USA, LLCTrulicity$235$80,54167 claims
Novo NordiskOzempic$641$75,39161 claims
PfizerEliquis$198$69,86466 claims
Boehringer IngelheimJardiance$82$28,39232 claims
MerckJanuvia$12$27,76523 claims
Johnson & JohnsonXarelto$17$20,12912 claims
GSKTrelegy Ellipta$164$16,11223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,332 family providers in Virginia.

Other family in Norfolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →